Roger B. Cohen

Roger B. Cohen's AcademicInfluence.com Rankings

Roger B. Cohen

Philosophy

#9690

World Rank

#13286

Historical Rank

Logic

#6659

World Rank

#8197

Historical Rank

philosophy Degrees

Download Badge

Philosophy

Roger B. Cohen's Degrees

Doctorate Medicine University of California, San Francisco

Why Is Roger B. Cohen Influential?

(Suggest an Edit or Addition)

(See a Problem?)

Roger B. Cohen's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. (2006) (4805)
Radiotherapy plus cetuximab for locoregionally advanced head and neck cancer: 5-year survival data from a phase 3 randomised trial, and relation between cetuximab-induced rash and survival. (2010) (1824)
Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer. (2007) (1535)
Anti-NKG2A mAb Is a Checkpoint Inhibitor that Promotes Anti-tumor Immunity by Unleashing Both T and NK Cells (2018) (629)
Axitinib is an active treatment for all histologic subtypes of advanced thyroid cancer: results from a phase II study. (2008) (626)
Phase I pharmacokinetic and pharmacodynamic study of the oral, small-molecule mitogen-activated protein kinase kinase 1/2 inhibitor AZD6244 (ARRY-142886) in patients with advanced cancers. (2008) (603)
Phase I pharmacologic and biologic study of ramucirumab (IMC-1121B), a fully human immunoglobulin G1 monoclonal antibody targeting the vascular endothelial growth factor receptor-2. (2010) (489)
T-Cell-Inflamed Gene-Expression Profile, Programmed Death Ligand 1 Expression, and Tumor Mutational Burden Predict Efficacy in Patients Treated With Pembrolizumab Across 20 Cancers: KEYNOTE-028. (2019) (481)
1,25-Dihydroxyvitamin D3 Suppresses Renin Gene Transcription by Blocking the Activity of the Cyclic AMP Response Element in the Renin Gene Promoter* (2007) (459)
Activity of XL184 (Cabozantinib), an oral tyrosine kinase inhibitor, in patients with medullary thyroid cancer. (2011) (412)
Pretreatment neutrophil-to-lymphocyte ratio as a marker of outcomes in nivolumab-treated patients with advanced non-small-cell lung cancer. (2017) (361)
Phase I pharmacokinetic and biologic correlative study of mapatumumab, a fully human monoclonal antibody with agonist activity to tumor necrosis factor-related apoptosis-inducing ligand receptor-1. (2007) (324)
Safety and Antitumor Activity of Pembrolizumab in Patients With Programmed Death-Ligand 1-Positive Nasopharyngeal Carcinoma: Results of the KEYNOTE-028 Study. (2017) (292)
Clinical Implications of Plasma-Based Genotyping With the Delivery of Personalized Therapy in Metastatic Non–Small Cell Lung Cancer (2019) (276)
Detection of Therapeutically Targetable Driver and Resistance Mutations in Lung Cancer Patients by Next-Generation Sequencing of Cell-Free Circulating Tumor DNA (2016) (270)
Randomized phase II study of BR96-doxorubicin conjugate in patients with metastatic breast cancer. (1999) (245)
Phase I trial of a melanoma vaccine with gp100(280-288) peptide and tetanus helper peptide in adjuvant: immunologic and clinical outcomes. (2001) (237)
Cetuximab prolongs survival in patients with locoregionally advanced squamous cell carcinoma of head and neck: A phase III study of high dose radiation therapy with or without cetuximab. (2004) (237)
Quality of life in head and neck cancer patients after treatment with high-dose radiotherapy alone or in combination with cetuximab. (2007) (229)
A Phase II Study of PD-0325901, an Oral MEK Inhibitor, in Previously Treated Patients with Advanced Non–Small Cell Lung Cancer (2010) (223)
Phase II study of lapatinib in recurrent or metastatic epidermal growth factor receptor and/or erbB2 expressing adenoid cystic carcinoma and non adenoid cystic carcinoma malignant tumors of the salivary glands. (2007) (208)
The relationship between infliximab treatment and lymphoma in Crohn's disease. (1999) (200)
Pembrolizumab After Completion of Locally Ablative Therapy for Oligometastatic Non-Small Cell Lung Cancer: A Phase 2 Trial. (2019) (180)
Safety and antitumor activity of the anti–PD-1 antibody pembrolizumab in patients with advanced colorectal carcinoma (2017) (179)
Phase I dose-escalation study of LCL161, an oral inhibitor of apoptosis proteins inhibitor, in patients with advanced solid tumors. (2014) (153)
Phase I Study of Aurora A Kinase Inhibitor MLN8237 in Advanced Solid Tumors: Safety, Pharmacokinetics, Pharmacodynamics, and Bioavailability of Two Oral Formulations (2012) (146)
A Randomized, Phase II Trial of Two Dose Levels of Temsirolimus (CCI-779) in Patients with Extensive-Stage Small-Cell Lung Cancer Who Have Responding or Stable Disease after Induction Chemotherapy: A Trial of the Eastern Cooperative Oncology Group (E1500) (2007) (143)
Sequential therapy for the locally advanced larynx and hypopharynx cancer subgroup in TAX 324: survival, surgery, and organ preservation. (2009) (138)
Phase II Efficacy and Pharmacogenomic Study of Selumetinib (AZD6244; ARRY-142886) in Iodine-131 Refractory Papillary Thyroid Carcinoma with or without Follicular Elements (2012) (132)
Phase I Study of the Investigational NEDD8-Activating Enzyme Inhibitor Pevonedistat (TAK-924/MLN4924) in Patients with Advanced Solid Tumors (2015) (130)
Mapatumumab, an antibody targeting TRAIL-R1, in combination with paclitaxel and carboplatin in patients with advanced solid malignancies: results of a phase I and pharmacokinetic study. (2009) (128)
Total Laryngectomy Versus Larynx Preservation for T4a Larynx Cancer: Patterns of Care and Survival Outcomes. (2015) (124)
Effects of food on the relative bioavailability of lapatinib in cancer patients. (2009) (124)
Pembrolizumab for the Treatment of Advanced Salivary Gland Carcinoma (2018) (122)
Current challenges and clinical investigations of epidermal growth factor receptor (EGFR)- and ErbB family-targeted agents in the treatment of head and neck squamous cell carcinoma (HNSCC). (2014) (120)
Epidermal growth factor receptor as a therapeutic target in colorectal cancer. (2003) (117)
Multicenter, randomized, phase II trial of CI-1033, an irreversible pan-ERBB inhibitor, for previously treated advanced non small-cell lung cancer. (2007) (115)
Safety and antitumor activity of the anti-PD-1 antibody pembrolizumab in patients with recurrent carcinoma of the anal canal (2017) (113)
Safety of Abatacept Administered Intravenously in Treatment of Rheumatoid Arthritis: Integrated Analyses of up to 8 Years of Treatment from the Abatacept Clinical Trial Program (2013) (110)
Phase 1 trial of the antiangiogenic peptide ATN-161 (Ac-PHSCN-NH2), a beta integrin antagonist, in patients with solid tumours (2006) (110)
Multicenter phase II study of oral bexarotene for patients with metastatic breast cancer. (2003) (110)
Safety and antitumor activity of the anti-PD-1 antibody pembrolizumab in patients with recurrent carcinoma of the anal canal (2017) (102)
A common protein binds to two silencers 5′ to the human β-globin gene (1989) (92)
Antiangiogenic therapy for advanced renal cell carcinoma: Management of treatment-related toxicities (2012) (87)
The role of cetuximab for the treatment of squamous cell carcinoma of the head and neck. (2008) (86)
Pembrolizumab for the treatment of programmed death–ligand 1‒positive advanced carcinoid or pancreatic neuroendocrine tumors: Results from the KEYNOTE‐028 study (2020) (85)
Phase I study of the safety, tolerability, and pharmacokinetics of oral CP-868,596, a highly specific platelet-derived growth factor receptor tyrosine kinase inhibitor in patients with advanced cancers. (2009) (85)
A Phase I Dose-Escalation Study of Danusertib (PHA-739358) Administered as a 24-Hour Infusion with and without Granulocyte Colony-Stimulating Factor in a 14-Day Cycle in Patients with Advanced Solid Tumors (2009) (84)
Identification of sequences within the murine granulocyte-macrophage colony-stimulating factor mRNA 3'-untranslated region that mediate mRNA stabilization induced by mitogen treatment of EL-4 thymoma cells. (1991) (81)
Targeting signal transduction pathways in colorectal cancer--more than skin deep. (2005) (80)
Immunotherapy Targeting HPV16/18 Generates Potent Immune Responses in HPV-Associated Head and Neck Cancer (2018) (78)
A randomized, phase II trial of cetuximab with or without PX-866, an irreversible oral phosphatidylinositol 3-kinase inhibitor, in patients with relapsed or metastatic head and neck squamous cell cancer. (2015) (77)
Post-transcriptional regulation of granulocyte-macrophage colony-stimulating factor synthesis in murine T cells. (1990) (75)
Cancer Communication in the Social Media Age. (2016) (71)
Interim results of an ongoing Phase I, dose escalation study of MGA271 (Fc-optimized humanized anti-B7-H3 monoclonal antibody) in patients with refractory B7-H3-expressing neoplasms or neoplasms whose vasculature expresses B7-H3 (2015) (70)
Phase 1 study of MLN8054, a selective inhibitor of Aurora A kinase in patients with advanced solid tumors (2011) (69)
A Phase II Trial of Alternative Volumes of Oropharyngeal Irradiation for De-intensification (AVOID): Omission of the Resected Primary Tumor Bed Following Transoral Robotic Surgery for Human Papilloma Virus Related Squamous Cell Carcinoma of the Oropharynx. (2019) (66)
Safety, Pharmacokinetics, and Pharmacodynamics of the Insulin-Like Growth Factor Type 1 Receptor Inhibitor Figitumumab (CP-751,871) in Combination with Paclitaxel and Carboplatin (2009) (66)
Partial purification of a nuclear protein that binds to the CCAAT box of the mouse alpha 1-globin gene (1986) (65)
Toxicity and outcome analysis of patients with recurrent head and neck cancer treated with hyperfractionated split‐course reirradiation and concurrent cisplatin and paclitaxel chemotherapy from two prospective phase I and II studies (2005) (64)
Phase I dose escalation, pharmacokinetic and pharmacodynamic study of naptumomab estafenatox alone in patients with advanced cancer and with docetaxel in patients with advanced non-small-cell lung cancer. (2009) (63)
Cisplatin Every 3 Weeks Versus Weekly With Definitive Concurrent Radiotherapy for Squamous Cell Carcinoma of the Head and Neck. (2018) (63)
Impact of neck dissection on long‐term feeding tube dependence in patients with head and neck cancer treated with primary radiation or chemoradiation (2009) (62)
Concentrations of calcitonin and catecholamines in pheochromocytomas, a mucosal neuroma and medullary thyroid carcinoma. (1973) (61)
Ca2+ ionophore A23187-dependent stabilization of granulocyte-macrophage colony-stimulating factor messenger RNA in murine thymoma EL-4 cells is mediated through two distinct regions in the 3'-untranslated region. (1993) (60)
Clinical responses to selumetinib (AZD6244; ARRY‐142886)‐based combination therapy stratified by gene mutations in patients with metastatic melanoma (2013) (59)
HPV‐related oropharyngeal cancer: Risk factors for treatment failure in patients managed with primary transoral robotic surgery (2016) (58)
Scan-associated distress in lung cancer: Quantifying the impact of "scanxiety". (2016) (55)
Binding of sequence-specific proteins to the adenosine- plus uridine-rich sequences of the murine granulocyte/macrophage colony-stimulating factor mRNA. (1992) (54)
Baseline Plasma Tumor Mutation Burden Predicts Response to Pembrolizumab-based Therapy in Patients with Metastatic Non–Small Cell Lung Cancer (2020) (53)
Nucleosome disruption precedes transcription and is largely limited to the transcribed domain of globin genes in murine erythroleukemia cells. (1985) (53)
Schilder's disease. Sex-linked recessive transmission with specific adrenal changes. (1972) (52)
427OPembrolizumab for patients with PD-L1–positive advanced carcinoid or pancreatic neuroendocrine tumors: Results from the KEYNOTE-028 study (2017) (52)
Phase I study of every 2- or 3-week dosing of ramucirumab, a human immunoglobulin G1 monoclonal antibody targeting the vascular endothelial growth factor receptor-2 in patients with advanced solid tumors. (2015) (52)
EGFR-targeting monoclonal antibodies in head and neck cancer. (2006) (51)
Solubilization of the UDP-glucose:1,4-beta-D-glucan 4-beta-D-glucosyltransferase (cellulose synthase) from Acetobacter xylinum. A comparison of regulatory properties with those of the membrane-bound form of the enzyme. (1983) (51)
Phase II Study of Paclitaxel, Carboplatin, and Cetuximab as First Line Treatment, for Patients with Advanced Non-small Cell Lung Cancer (NSCLC): Results of OPN-017 (2008) (51)
Impact of KRAS and TP53 Co-Mutations on Outcomes After First-Line Systemic Therapy Among Patients With STK11-Mutated Advanced Non-Small-Cell Lung Cancer. (2019) (50)
Influence of TP53 Mutation on Survival in Patients With Advanced EGFR-Mutant Non-Small-Cell Lung Cancer. (2018) (49)
The contribution of cetuximab in the treatment of recurrent and/or metastatic head and neck cancer (2010) (48)
A phase I study of the safety and pharmacokinetics of trabectedin in combination with pegylated liposomal doxorubicin in patients with advanced malignancies. (2008) (47)
Transoral Robotic Surgery–Assisted Endoscopy With Primary Site Detection and Treatment in Occult Mucosal Primaries (2017) (47)
Phase I assessment of new mechanism-based pharmacodynamic biomarkers for MLN8054, a small-molecule inhibitor of Aurora A kinase. (2011) (47)
Phase Ib study of pevonedistat, a NEDD8-activating enzyme inhibitor, in combination with docetaxel, carboplatin and paclitaxel, or gemcitabine, in patients with advanced solid tumors (2018) (47)
Anti-TNF therapy and malignancy - a critical review. (2001) (45)
Phase I/II study of intermittent all-trans-retinoic acid, alone and in combination with interferon alfa-2a, in patients with epidemic Kaposi's sarcoma. (1995) (45)
An open-label clinical trial evaluating safety and pharmacokinetics of two dosing schedules of panitumumab in patients with solid tumors. (2009) (43)
Phase I Safety and Pharmacokinetic Study of the PI3K/mTOR Inhibitor SAR245409 (XL765) in Combination with Erlotinib in Patients with Advanced Solid Tumors (2014) (42)
Prospective study of proton‐beam radiation therapy for limited‐stage small cell lung cancer (2017) (42)
Management of Lung Cancer During the COVID-19 Pandemic. (2020) (42)
A phase I dose-finding, safety and tolerability study of AZD8330 in patients with advanced malignancies. (2013) (42)
Use of the aromatase inhibitor anastrozole in the treatment of patients with advanced prostate carcinoma (2001) (41)
A Phase I, open-label, dose escalation study of afatinib, in a 3-week-on/1-week-off schedule in patients with advanced solid tumors (2012) (41)
Regulation of eukaryotic translation initiation factor expression during T-cell activation. (1993) (40)
Circulating tumor cells as a predictive biomarker in patients with small cell lung cancer undergoing chemotherapy. (2017) (39)
Targeting epidermal growth factor receptor signaling in the treatment of head and neck cancer (2006) (39)
Fluorescence in situ hybridization gene amplification analysis of EGFR and HER2 in patients with malignant salivary gland tumors treated with lapatinib (2009) (39)
Efficacy of the anti-insulin like growth factor I receptor (IGF-IR) antibody CP-751871 in combination with paclitaxel and carboplatin as first-line treatment for advanced non-small cell lung cancer (NSCLC) (2007) (37)
A randomized, phase II ECOG trial of two dose levels of temsirolimus (CCI-779) in patients with extensive stage small cell lung cancer in remission after induction chemotherapy. A preliminary report (2005) (36)
Association Between KRAS Variant Status and Outcomes With First-line Immune Checkpoint Inhibitor-Based Therapy in Patients With Advanced Non-Small-Cell Lung Cancer. (2021) (35)
Evaluating the safety and efficacy of axitinib in the treatment of advanced renal cell carcinoma (2015) (35)
Acute Stress Disorder Following Diagnosis of Cancer (1998) (35)
Immunotherapy for head and neck cancer: where are we now and where are we going? (2019) (35)
Late consequential surgical bed soft tissue necrosis in advanced oropharyngeal squamous cell carcinomas treated with transoral robotic surgery and postoperative radiation therapy. (2012) (35)
Identification and characterization of a novel transcription factor participating in the expression of eukaryotic initiation factor 2 alpha. (1989) (34)
The distribution of immunoreactive chromogranins, S-100 protein, and vasoactive intestinal peptide in compound tumors of the adrenal medulla. (1987) (34)
Research participants' high expectations of benefit in early-phase oncology trials: are we asking the right question? (2012) (33)
Efficacy of the nanoparticle-drug conjugate CRLX101 in combination with bevacizumab in metastatic renal cell carcinoma: results of an investigator-initiated phase I-IIa clinical trial. (2016) (32)
Surgical pathology of hyperparathyroidism. Usefulness of fat stain and problems in interpretation. (1981) (32)
Beyond Positive Margins and Extracapsular Extension: Evaluating the Utilization and Clinical Impact of Postoperative Chemoradiotherapy in Resected Locally Advanced Head and Neck Cancer. (2017) (31)
HGS-ETR1, an antibody targeting TRAIL-R1, in combination with paclitaxel and carboplatin in patients with advanced solid malignancies: Results of a phase 1 and PK study. (2006) (31)
A first-in-human study of the anti-α5β1 integrin monoclonal antibody PF-04605412 administered intravenously to patients with advanced solid tumors (2014) (30)
Breast lymphoma. A clinical and pathological review and 10-year treatment results. (1995) (30)
Prospective clinical trial to compare vincristine and vinblastine in a COP-based protocol for lymphoma in cats. (2013) (30)
Ossified pulmonary metastases from giant cell tumor of bone. (1976) (29)
Phase II Study of Lapatinib in Recurrent or Metastatic Epidermal Growth Factor Receptor and / or erbB 2 Expressing Adenoid Cystic Carcinoma and Non – Adenoid Cystic Carcinoma Malignant Tumors of the Salivary Glands (2007) (28)
315O_PRAntitumor activity and safety of pembrolizumab in patients with PD-L1-positive nasopharyngeal carcinoma: Interim results from a phase 1b study (2015) (28)
A phase 2 study of dalantercept, an activin receptor‐like kinase‐1 ligand trap, in patients with recurrent or metastatic squamous cell carcinoma of the head and neck (2016) (28)
A phase I trial of KX2-391, a novel non-ATP competitive substrate-pocket- directed SRC inhibitor, in patients with advanced malignancies (2013) (27)
A phase II study of axitinib (AG-013736 [AG]) in patients (pts) with advanced thyroid cancers (2007) (27)
Long-term results in a cohort of medullary thyroid cancer (MTC) patients (pts) in a phase I study of XL184 (BMS 907351), an oral inhibitor of MET, VEGFR2, and RET. (2010) (26)
An empirical antigen selection method identifies neoantigens that either elicit broad anti-tumor T cell responses or drive tumor growth. (2021) (26)
Safety, tolerability, and pharmacokinetics of TAK-701, a humanized anti-hepatocyte growth factor (HGF) monoclonal antibody, in patients with advanced nonhematologic malignancies: First-in-human phase I dose-escalation study. (2010) (26)
Phase I trial of axitinib combined with platinum doublets in patients with advanced non-small cell lung cancer and other solid tumours (2012) (26)
EGFR-targeting monoclonal antibodies in head and neck cancer. (2006) (25)
First-in-human dose-escalation safety and PK trial of a novel intravenous humanized monoclonal CovX body inhibiting angiopoietin 2. (2010) (25)
DNA affinity labeling of adenovirus type 2 upstream promoter sequence-binding factors identifies two distinct proteins (1988) (25)
Structural Variations in the Adult Ovary—Clinical Significance (1965) (25)
Phase I study of axitinib combined with paclitaxel, docetaxel or capecitabine in patients with advanced solid tumours (2012) (24)
First-in-Human Phase I Study of Merestinib, an Oral Multikinase Inhibitor, in Patients with Advanced Cancer. (2019) (24)
Risk of lymph node metastasis and recommendations for elective nodal treatment in squamous cell carcinoma of the nasal cavity and maxillary sinus: a SEER analysis (2016) (24)
Phase I study of the investigational drug MLN8237, an Aurora A kinase (AAK) inhibitor, in patients (pts) with solid tumors. (2010) (24)
The association between fatigue and pain symptoms and decreased physical activity after cancer (2018) (24)
Combination of monalizumab and cetuximab in recurrent or metastatic head and neck cancer patients previously treated with platinum-based chemotherapy and PD-(L)1 inhibitors. (2020) (24)
A phase I safety and pharmacokinetic (PK) study of PI3K/TORC1/TORC2 inhibitor XL765 (SAR245409) in combination with erlotinib (E) in patients (pts) with advanced solid tumors. (2010) (24)
A phase I dose escalation study of BIBW 2992, an irreversible dual EGFR/HER2 receptor tyrosine kinase inhibitor, in a 3 week on 1 week off schedule in patients with advanced solid tumors. (2006) (23)
Dual checkpoint targeting of B7-H3 and PD-1 with enoblituzumab and pembrolizumab in advanced solid tumors: interim results from a multicenter phase I/II trial (2022) (23)
A multicenter phase 1 study of PX-866 and cetuximab in patients with metastatic colorectal carcinoma or recurrent/metastatic squamous cell carcinoma of the head and neck (2014) (22)
Oxidative‐Enzyme Activity in Normal and Pathologic Human Ovaries (1964) (22)
Survival outcome according to KRAS mutation status in newly diagnosed patients with stage IV non-small cell lung cancer treated with platinum doublet chemotherapy (2015) (21)
A Phase I Study of the Anti-Activin Receptor-Like Kinase 1 (ALK-1) Monoclonal Antibody PF-03446962 in Patients with Advanced Solid Tumors (2015) (21)
Quality of Life of Postoperative Photon versus Proton Radiation Therapy for Oropharynx Cancer (2018) (21)
Cisplatin versus cetuximab with definitive concurrent radiotherapy for head and neck squamous cell carcinoma: An analysis of Veterans Health Affairs data (2018) (21)
Nodal metastasis and elective nodal level treatment in sinonasal small-cell and sinonasal undifferentiated carcinoma: a surveillance, epidemiology and end results analysis. (2016) (21)
Identification and characterization of an adenovirus 2 major late promoter CAP sequence DNA-binding protein. (1990) (21)
Capecitabine and lapatinib for the first‐line treatment of metastatic/recurrent head and neck squamous cell carcinoma (2016) (21)
Barriers to physical activity: a study of academic and community cancer survivors with pain (2018) (20)
Immunotherapy for head and neck cancer: latest developments and clinical potential (2016) (20)
Uptake and Survival Outcomes Following Immune Checkpoint Inhibitor Therapy Among Trial-Ineligible Patients With Advanced Solid Cancers. (2021) (20)
A phase I dose-escalation study of weekly IMC-1121B, a fully human anti-vascular endothelial growth factor receptor 2 (VEGFR2) IgG1 monoclonal antibody (Mab), in patients (pts) with advanced cancer. (2006) (20)
IL-1 alpha induces granulocyte-macrophage colony-stimulating factor gene expression in murine B lymphocyte cell lines via mRNA stabilization. (1991) (20)
Risk factors for development of sterile haemorrhagic cystitis in canine lymphoma patients receiving oral cyclophosphamide: a case-control study. (2014) (20)
Abstract 2775: A phase I study of LCL161, an oral IAP inhibitor, in patients with advanced cancer (2010) (20)
Two Phase 1 dose-escalation studies exploring multiple regimens of litronesib (LY2523355), an Eg5 inhibitor, in patients with advanced cancer (2017) (20)
Evidence of acute stress disorder after diagnosis of cancer. (1998) (19)
Effect of Prophylactic Cranial Irradiation on Overall Survival in Metastatic Small‐Cell Lung Cancer: A Propensity Score‐Matched Analysis (2017) (19)
Isolation and characterization of the promoter and flanking regions of the gene encoding the human protein-synthesis-initiation factor 2α (1989) (19)
A phase I and pharmacokinetic study of HGS-ETR1(TRM-1), a human monoclonal agonist-antibody to TRAIL R1, in patients with advanced solid tumors (2004) (19)
What if Acupuncture Were Covered by Insurance for Pain Management? A Cross-Sectional Study of Cancer Patients at One Academic Center and 11 Community Hospitals. (2019) (18)
A phase I dose-escalation study of weekly IMC-1121B, a fully human anti-vascular endothelial growth factor receptor 2 (VEGFR2) IgG1 monoclonal antibody (Mab), in patients (pts) with advanced cancer (2006) (18)
A phase I safety, pharmacological and biological study of the farnesyl protein transferase inhibitor, tipifarnib and capecitabine in advanced solid tumors. (2006) (18)
500 Pembrolizumab (MK-3475) for PD-L1-positive squamous cell carcinoma (SCC) of the anal canal: Preliminary safety and efficacy results from KEYNOTE-028 (2015) (18)
Identification of a downstream sequence and binding protein that regulate adenovirus major late promoter transcription in vitro. (1988) (17)
A case of acromegaly identified after patient complaint of apertognathia. (1993) (17)
Phase II study and tissue correlative studies of AZD6244 (ARRY-142886) in iodine-131 refractory papillary thyroid carcinoma (IRPTC) and papillary thyroid carcinoma (PTC) with follicular elements. (2010) (17)
A phase 1, open-label, dose-escalation study of BIIB022 (anti-IGF-1R monoclonal antibody) in subjects with relapsed or refractory solid tumors (2014) (17)
Identifying predictors of HPV‐related head and neck squamous cell carcinoma progression and survival through patient‐derived models (2020) (17)
Comparative Effectiveness of Carboplatin/Pemetrexed With Versus Without Bevacizumab for Advanced Nonsquamous Non-Small Cell Lung Cancer. (2019) (17)
Serial Monitoring of Circulating Tumor DNA by Next-Generation Gene Sequencing as a Biomarker of Response and Survival in Patients With Advanced NSCLC Receiving Pembrolizumab-Based Therapy (2021) (17)
Phase I study of PF-03446962, a fully human mAb against ALK 1, a TGFβ receptor involved in tumor angiogenesis. (2010) (16)
Increased Recurrences Using Intensity-Modulated Radiation Therapy in the Postoperative Setting (2010) (16)
Results of a phase II study evaluating monalizumab in combination with cetuximab in previously treated recurrent or metastatic squamous cell carcinoma of the head and neck (R/M SCCHN). (2018) (16)
Phase II Evaluation of 96-Hour Paclitaxel Infusion in Advanced (Recurrent or Metastatic) Squamous Cell Carcinoma of the Head and Neck (E3395): A Trial of the Eastern Cooperative Oncology Group (2004) (16)
Exposure–response relationship for ramucirumab from the randomized, double-blind, phase 3 REVEL trial (docetaxel versus docetaxel plus ramucirumab) in second-line treatment of metastatic non-small cell lung cancer (2018) (15)
A phase I/randomized phase II, non-comparative, multicenter, open label trial of CP-547,632 in combination with paclitaxel and carboplatin or paclitaxel and carboplatin alone as first-line treatment for advanced non-small cell lung cancer (NSCLC) (2007) (15)
Case report 377: Intraosseous lipoma (angiolipoma) of right third rib. (1986) (15)
Phase I study of the pan aurora kinases (AKs) inhibitor PHA-739358 administered as a 24 h infusion without/with G-CSF in a 14-day cycle in patients with advanced solid tumors (2008) (15)
Results of a phase I trial of KX2-391, a novel non-ATP competitive substrate-pocket directed SRC inhibitor, in patients with advanced malignancies. (2009) (15)
Interferon-alpha induced autoimmune hepatitis in a patient with Philadelphia chromosome-positive chronic myeloid leukemia with cytogenetically normal T lymphocytes. (1992) (15)
Oncologic and survival outcomes for resectable locally-advanced HPV-related oropharyngeal cancer treated with transoral robotic surgery. (2021) (15)
A phase II study of lapatinib in recurrent or metastatic EGFR and/or ErbB2 expressing adenoid cystic (ACC) and non-ACC malignant tumors of the salivary glands (MSGT). (2006) (14)
A phase I study of the safety and pharmacokinetics of edotecarin (J-107088), a novel topoisomerase I inhibitor, in patients with advanced solid tumors (2006) (14)
Phase I trial of oral CP-547,632 (VEGFR2) in combination with paclitaxel (P) and carboplatin (C) in advanced non-small cell lung cancer (NSCLC). (2004) (14)
280 POSTER Phase I study of the safety, pharmacokinetics (PK), and pharmacodynamics (PD) of MLN8237, a selective Aurora A kinase inhibitor, in the United States (2008) (14)
Monalizumab in combination with cetuximab in patients (pts) with recurrent or metastatic (R/M) head and neck cancer (SCCHN) previously treated or not with PD-(L)1 inhibitors (IO): 1-year survival data (2019) (14)
A phase 1 study of enoblituzumab in combination with pembrolizumab in patients with advanced B7-H3-expressing cancers. (2016) (14)
Phase I clinical trial of MLN8054, a selective inhibitor of Aurora A kinase (2007) (14)
Preliminary results for the advanced salivary gland carcinoma cohort of the phase 1b KEYNOTE-028 study of pembrolizumab. (2016) (13)
Immunotherapy with VGX-3100 (HPV16 and HPV18 plasmids) + INO-9012 (DNA encoding IL-12) in human papillomavirus (HPV) associated head and neck squamous cell carcinoma (HNSCCa): interim safety and immunogenicity results (2015) (13)
Phase 1 Experience with an Anti-Glycotope Monoclonal Antibody, RAV12, in Recurrent Adenocarcinoma (2010) (13)
Phase I Study of Intrapleural Gene-Mediated Cytotoxic Immunotherapy in Patients with Malignant Pleural Effusion. (2018) (13)
Outcomes in Patients With Non-small-cell Lung Cancer With Brain Metastases Treated With Pembrolizumab-based Therapy. (2020) (13)
Immune Therapy Targeting E6/E7 Oncogenes of Human Papillomavirus Type 6 (HPV-6) Reduces or Eliminates the Need for Surgical Intervention in the Treatment of HPV-6 Associated Recurrent Respiratory Papillomatosis (2020) (12)
A phase I dose-escalation study of selumetinib in combination with docetaxel or dacarbazine in patients with advanced solid tumors (2017) (12)
Combining immunotherapy and radiation therapy for small cell lung cancer and thymic tumors. (2007) (12)
Phase I study of every 2- or 3-week dosing of ramucirumab, a human immunoglobulin G1 monoclonal antibody targeting the vascular endothelial growth factor receptor-2 in patients with advanced solid tumors. (2015) (12)
Emerging uses of circulating tumor DNA in advanced stage non-small cell lung cancer. (2017) (12)
Abstract B225: A phase I dose-escalation study of selumetinib in combination with docetaxel in patients with advanced solid tumors. (2011) (12)
A Phase II study of axitinib (AG-013736), a potent inhibitor of VEGFRs, in patients with advanced thyroid cancer. (2007) (12)
Care of immunocompromised patients with head and neck cancer during the COVID‐19 pandemic: Two challenging and informative clinical cases (2020) (11)
Acupuncture for Dyspnea in Lung Cancer (2016) (11)
A Phase II study of axitinib (AG-013736), a potent inhibitor of VEGFRs, in patients with advanced thyroid cancer (2006) (11)
31st Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2016): part two (2016) (11)
Phase I Study of Weekly Vinorelbine in Combination with Weekly Paclitaxel in Adult Patients with Advanced Refractory Cancer (2000) (11)
Phase I dose escalation and pharmacokinetic evaluation of two different schedules of LY2334737, an oral gemcitabine prodrug, in patients with advanced solid tumors (2015) (11)
Treatment of corticosteroid refractory immune checkpoint inhibitor myocarditis with Infliximab: a case series (2021) (11)
Sunitinib in combination with paclitaxel plus carboplatin in patients with advanced solid tumors: phase I study results (2011) (10)
Safety and tolerability of the anti-IGF-I receptor antibody CP-751,871 in combination with paclitaxel and carboplatin in patients with advanced solid tumors (2007) (10)
Phase I study of trabectedin (T) in combination with docetaxel (D) in patients with advanced malignancies. (2006) (10)
Unexpected dementia following prophylactic cranial irradiation for small cell lung cancer: case report (2007) (10)
Final results of a combination study between trabectedin and pegylated liposomal doxorubicin (PLD) in patients with advanced malignancies (2005) (10)
Axitinib (AG-013736; AG) combined with chemotherapy in patients (pts) with advanced non-small cell lung cancer (NSCLC) and other solid tumors. (2016) (10)
Statistical Considerations in Clinical Trial Design of Immunotherapeutic Cancer Agents. (2015) (10)
Antiemetic efficacy of single-dose oral granisetron (1 mg vs 2 mg) with moderately emetogenic chemotherapy. (2000) (10)
Pharmacokinetic (PK) and pharmacodynamic (PD) results from two phase I studies of the investigational selective Aurora A kinase (AAK) inhibitor MLN8237: Exposure-dependent AAK inhibition in human tumors. (2010) (10)
Increased rate of recurrence and high rate of salvage in patients with human papillomavirus–associated oropharyngeal squamous cell carcinoma with adverse features treated with primary surgery without recommended adjuvant therapy (2020) (10)
Etirinotecan Pegol (NKTR‐102) in Third‐line Treatment of Patients With Metastatic or Recurrent Non–Small‐cell Lung Cancer: Results of a Phase II Study (2017) (10)
A common protein binds to two silencers 5' to the human beta-globin gene. (1989) (10)
A phase I dose-escalation study of Selumetinib in combination with Erlotinib or Temsirolimus in patients with advanced solid tumors (2017) (10)
Phase III evaluation of radiation with and without cetuximab for locoregionally advanced head and neck cancer (2004) (9)
Unsupervised exercise in survivors of human papillomavirus related head and neck cancer: how many can go it alone? (2017) (9)
Locoregional Recurrence in p16‐Positive Oropharyngeal Squamous Cell Carcinoma After TORS (2021) (9)
First-in-human dose escalation safety and pharmacokinetic (PK) trial of a novel intravenous (IV) thrombospondin-1 (TSP-1) mimetic humanized monoclonal CovX Body (CVX-045) in patients (pts) with advanced solid tumors (2008) (9)
Pharmacokinetic results from two phase I dose escalation studies of once daily oral treatment with BIBW 2992, an irreversible dual EGFR/HER2 receptor tyrosine kinase inhibitor, in patients with advanced solid tumors. (2005) (9)
Abstract CT158: Phase II study of monalizumab, a first-in-class NKG2A monoclonal antibody, in combination with cetuximab in previously treated recurrent or metastatic squamous cell carcinoma of the head and neck (R/M SCCHN): Preliminary assessment of safety and efficacy (2018) (9)
Interaction of CAP sequence site binding factor and transcription factor IID preceding and following binding to the adenovirus 2 major late promoter. (1991) (9)
Assessment of trabectedin (T) induced liver toxicity with correlation to liver morphology in a phase I study of T + pegylated liposomal doxorubicin (PLD). (2006) (9)
New agents in the treatment for malignancies of the salivary and thyroid glands. (2008) (9)
Clinical application of EGFR inhibitors in head and neck squamous cell cancer. (2008) (8)
Rituximab treatment in seronegative autoimmune autonomic neuropathy and autoimmune autonomic ganglionopathy: Case-report and literature review (2019) (7)
MLN4924, an investigational NEDD8-activating enzyme (NAE) inhibitor, in patients (pts) with advanced solid tumors: Phase I study of multiple treatment schedules. (2011) (7)
Targeting HER2/neu Oncogene Overexpression With Ado-Trastuzumab Emtansine in the Treatment of Metastatic Salivary Gland Neoplasms: A Single-Institution Experience. (2019) (7)
Promising Survival in Patients with Recurrent Non-small Cell Lung Cancer Treated with Docetaxel and Gemcitabine in Combination as Second-Line Therapy (2008) (7)
Penn Medicine Head and Neck Cancer Service Line COVID‐19 management guidelines (2020) (7)
Exposure-response relationship for ramucirumab (RAM) from the randomized, double-blind, phase III REVEL trial (docetaxel [DOC] vs DOC plus RAM) in second-line treatment of metastatic non-small cell lung cancer (NSCLC). (2015) (7)
The impact of treatment package time on locoregional control for HPV+ oropharyngeal squamous cell carcinoma treated with surgery and postoperative (chemo)radiation (2019) (7)
HPV-Related Oropharyngeal Cancer: Risk Factors for Treatment Failure in Patients Managed With Surgery (TORS) (2014) (6)
84PDRelationship of PD-L1 and a T-cell inflamed gene expression profile (GEP) to clinical response in a multicohort trial of solid tumors (KEYNOTE [KN]028) (2017) (6)
P3.02c-029 Immune-Related Adverse Events and Their Effect on Outcomes in Patients (pts) with Non-Small Cell Lung Cancer (NSCLC) Treated with Nivolumab: Topic: IT (2017) (6)
Nonsurgical management of oropharyngeal, laryngeal, and hypopharyngeal cancer: The Fox Chase Cancer Center experience (2011) (6)
GEN-009, a neoantigen vaccine containing ATLAS selected neoantigens, to generate broad sustained immunity against immunogenic tumor mutations and avoid inhibitory peptides. (2020) (6)
2801 Antitumor activity and safety of pembrolizumab in patients with PD-L1-positive nasopharyngeal carcinoma: Interim results from a hase 1b study (2015) (6)
P3.02c-028 Outcomes of Nivolumab in Elderly Patients (pts) with Non-Small Cell Lung Cancer (NSCLC): Topic: IT (2017) (6)
EGFR inhibitors for the treatment of squamous cell carcinoma of the head and neck (2008) (6)
Accrual of Black participants to cancer clinical trials following a five-year prospective initiative of community outreach and engagement. (2021) (5)
Bioequivalence study of a new oral topotecan formulation, relative to the current topotecan formulation, in patients with advanced solid tumors. (2009) (5)
Viagenpumatucel-L (HS-110) plus nivolumab in patients with advanced non-small cell lung cancer (NSCLC) after checkpoint inhibitor treatment failure. (2019) (5)
Interim results of a phase 1b/2a study evaluating the nano pharmaceutical CRLX101 with bevacizumab (bev) in the treatment of patients (pts) with refractory metastatic renal cell carcinoma (mRCC). (2014) (5)
Visual recovery after radiation therapy of orbital lymphoma. (1992) (5)
EGFr expression and clinical outcome in head and neck cancer patients treated with radiotherapy with or without cetuximab. (2006) (5)
Phase I study of intravenous CCI-779 in combination with bryostatin-1 in solid tumors. (2006) (5)
Cetuximab-Based vs Carboplatin-Based Chemoradiotherapy for Patients With Head and Neck Cancer. (2022) (5)
Myasthenia gravis. II. Histochemical demonstration of acetylcholinesterase activity in motor end-plates of extraocular muscle in patients with myasthenia gravis; a post-mortem study. (1959) (5)
Phase I study of the safety and pharmacokinetics of trabectedin with docetaxel in patients with advanced malignancies (2015) (5)
Definitive tumor directed therapy confers a survival advantage for metachronous oligometastatic HPV-associated oropharyngeal cancer following trans-oral robotic surgery. (2021) (5)
Concanavalin A-induced granulocyte-macrophage colony-stimulating factor production in a murine T-cell line is posttranscriptionally controlled. (1992) (5)
Phase 2 study of dalantercept in recurrent or metastatic squamous cell carcinoma of the head and neck. (2014) (5)
Plasma Genotyping at the Time of Diagnostic Tissue Biopsy Decreases Time-to-Treatment in Patients With Advanced NSCLC—Results From a Prospective Pilot Study (2022) (5)
Immunogenicity results using human papillomavirus (HPV) specific DNA vaccine, INO-3112 (HPV16/HPV18 plasmids + IL-12) in HPV+ head and neck squamous cell carcinoma (HNSCCa). (2017) (5)
Phase Ib study of pevonedistat , a NEDD 8-activating enzyme inhibitor , in combination with docetaxel , carboplatin and paclitaxel , or gemcitabine , in patients with advanced solid tumors (5)
Abstract 5666: Safety of the first-in-class anti-NKG2A monoclonal antibody monalizumab in combination with cetuximab: a phase Ib/II study in recurrent or metastatic squamous cell carcinoma of the head and neck (R/M SCCHN) (2017) (4)
Sunitinib in combination with paclitaxel and carboplatin in patients with advanced solid tumors: Updated phase I study results. (2016) (4)
MA25.04 Blood-Based Tumor Mutation Burden as a Predictive Biomarker for Outcomes After Pembrolizumab Based First Line Therapy in Metastatic NSCLC (2019) (4)
Association Between Up-front Surgery and Risk of Stroke in US Veterans With Oropharyngeal Carcinoma. (2022) (4)
Pharmacodynamic effects of MLN4924, a novel NAE inhibitor, on blood and skin. (2009) (4)
26 ORAL Phase Ib and pharmacodynamic study of the MEK inhibitor AZD6244 (ARRY-142886) in patients with advanced solid malignancies (2006) (4)
523 Preliminary clinical experience with XmAb20717, a PD-1 x CTLA-4 bispecific antibody, in patients with advanced solid tumors (2021) (4)
Long term results from a phase 1 trial of GEN-009, a personalized neoantigen vaccine, combined with PD-1 inhibition in advanced solid tumors. (2021) (4)
A Phase I, open-label, dose escalation study of MGA271 in combination with pembrolizumab in patients with B7-H3-expressing melanoma, squamous cell cancer of the head and neck, or squamous cell non-small cell lung cancer (2015) (4)
Administered as a 24-Hour Infusion with and without Granulocyte Colony-Stimulating Factor in a 14-Day Cycle in Patients with Advanced Solid Tumors (2009) (4)
Impact of Prophylactic Cranial Irradiation on Overall Survival in Metastatic Small Cell Lung Cancer: A Propensity Score Matched Analysis of Patients in the National Cancer Database. (2017) (4)
Abstract A1: Phase 1 study of PF-03446962, a fully human mAb against activin receptor-like kinase 1 (ALK 1), a TGFβ receptor involved in tumor angiogenesis. (2011) (4)
Isolation and characterization of the promoter and flanking regions of the gene encoding the human protein-synthesis-initiation factor 2 alpha. (1989) (4)
Benefits of omitting primary site radiation therapy after transoral robotic surgery: Only time will tell. (2017) (4)
Association of comprehensive molecular genotyping and overall survival in patients with advanced non-squamous non-small cell lung cancer. (2022) (4)
281 POSTER Phase I and pharmacokinetic study of MLN8054, a selective inhibitor of Aurora A kinase (2008) (4)
Oncologic outcomes of transoral robotic surgery for HPV‐negative oropharyngeal carcinomas (2021) (4)
Prolonged exposure to subcutaneous and intravenous abatacept in patients with rheumatoid arthritis does not affect rates of infection, malignancy and autoimmune events: results from pooled clinical trial data (2013) (4)
123MO Monalizumab, cetuximab and durvalumab in first-line treatment of recurrent or metastatic squamous cell carcinoma of the head and neck (R/M SCCHN): A phase II trial (2021) (4)
A benchmark for oncologic outcomes and model for lethal recurrence risk after transoral robotic resection of HPV-related oropharyngeal cancers. (2022) (4)
Phase I study of gene mediated cytotoxic immunotherapy (GMCI) for patients with malignant pleural effusion (MPE). (2016) (4)
343 POSTER Phase I dose escalation study of the aurora kinase inhibitor PHA-739358 administered as a 24 hours infusion in a 14-day cycle in patients with advanced/metastatic solid tumor (2006) (4)
A phase 1/2a study of GEN-009, a neoantigen vaccine based on autologous peptide immune responses. (2019) (4)
A phase I and pharmacokinetic study of HGS-ETR1(TRM-1), a human monoclonal agonist-antibody to TRAIL R1, in patients with advanced solid tumors. (2004) (3)
Lung Cancer–Related Mortality With Inhaled Insulin or a Comparator: Follow-Up Study of patients previously enrolled in Exubera Controlled Clinical Trials (FUSE) Final Results (2019) (3)
A randomized, double-blind phase II study of pembrolizumab versus placebo in patients with head and neck cancers at high risk for recurrence or low-volume residual disease: The PATHWay Study. (2017) (3)
Analysis of the Relationship Between Response to Chemotherapy and Response to Radiation Therapy in Patients With Non–Small Cell Lung Cancer Receiving Sequential Treatment (2016) (3)
An open label phase I study of ABR-217620, a fusion protein of the 5T4 antibody moiety and an engineered superantigen, in patients with non-small cell lung, renal cell or pancreatic cancer. (2006) (3)
Phase I study of sunitinib in combination with carboplatin (C) plus paclitaxel (P) in patients (pts) with advanced solid tumors (STs) (2008) (3)
Bilateral adrenal hemorrhage and adrenal insufficiency in a patient with lymphomatous adrenal infiltration following administration of a fusion toxin (DAB486 interleukin-2). (1994) (3)
407 Preliminary safety, pharmacokinetics/pharmacodynamics, and antitumor activity of XmAb20717, a PD-1 x CTLA-4 bispecific antibody, in patients with advanced solid tumors (2020) (3)
Combination lapatinib and capecitabine in advanced, incurable squamous cell carcinoma of the head and neck (SCCHN). (2013) (3)
The Role of Advanced Imaging in Assessing Response to Definitive Chemoradiation Before Prophylactic Cranial Irradiation in Limited‐Stage Small‐Cell Lung Cancer (2017) (3)
CDX3379-04: Phase II evaluation of CDX-3379 in combination with cetuximab in patients with advanced head and neck squamous cell carcinoma (HNSCC). (2019) (3)
Circulating immune complexes in primary biliary cirrhosis: interactions with lymphoid cells. (1982) (3)
30 A phase I clinical trial of HGS-ETR1, an agonist monoclonal antibody to TRAIL-R1, in patients with advanced solid tumors (2004) (3)
[Targeted agents in the treatment of lung cancer]. (2012) (3)
OA 17.08 Phase II Study of Pembrolizumab for Oligometastatic Non-Small Cell Lung Cancer (NSCLC) Following Completion of Locally Ablative Therapy (LAT) (2017) (3)
Pretreatment Red Blood Cell Total Folate Concentration Is Associated With Response to Pemetrexed in Stage IV Nonsquamous Non–Small‐cell Lung Cancer (2017) (3)
Risk of Post-Operative, Pre-Radiotherapy Contralateral Neck Recurrence in Patients Treated with Surgery Followed by Adjuvant Radiotherapy for Human Papilloma Virus-Associated Tonsil Cancer. (2019) (3)
Impact of telemedicine adoption on accessibility and time to treatment in patients with thoracic malignancies during the COVID-19 pandemic (2021) (3)
Abstract A86: A phase 1 study of LY2523355, an Eg5 inhibitor, administered on Days 1, 2, and 3 with or without pegfilgrastim in patients with advanced malignancy (NCT01214629). (2011) (3)
Phase I experience with an anti-glycotope monoclonal antibody, RAV12, in recurrent adenocarcinoma. (2006) (3)
1PDImmunotherapy with INO-3112 (HPV16 and HPV18 plasmids + IL-12 DNA) in human papillomavirus (HPV) associated head and neck squamous cell carcinoma (HNSCCa) (2015) (3)
398 POSTER Phase I, pharmacokinetic (PK), dose-escalation study of EZN-2968, a novel hypoxia-inducible factor-1 alpha (HIF-1a) antagonist, administered weekly in patients (pts) with solid tumours (2008) (3)
Abstract #3603: ARRY-334543 in ErbB2 positive metastatic breast cancer and other ErbB expressing-cancers: experience from expansion cohorts on a phase I study (2009) (3)
A phase 2, multicenter, open-label study to evaluate the efficacy and safety of CDX-3379 in combination with cetuximab in patients with advanced head and neck squamous cell carcinoma (HNSCC). (2018) (2)
Early Tumor and Nodal Response in Patients with Locally-advanced NSCLC Predict for Oncologic Outcomes in Patients Treated with Concurrent Proton Therapy and Chemotherapy: Tumor Regression Predicts Outcomes in LA-NSCLC. (2019) (2)
A phase I, pharmacological and biological study of weekly IMC-1121B, a recombinant human IgG1 monoclonal antibody (MAb), targeting vascular endothelial growth factor receptor 2 (VEGFR-2), in patients (pts) with advanced solid tumors. (2007) (2)
Phase I dose-escalation study of cabazitaxel administered in combination with gemcitabine in patients with metastatic or unresectable advanced solid malignancies (2015) (2)
Oncologic Outcomes Following Transoral Robotic Surgery for Human Papillomavirus-Associated Oropharyngeal Carcinoma in Older Patients. (2020) (2)
Analysis of ERCC1 (excision repair cross complementing group 1) in squamous cell carcinoma of the head and neck (SCCHN) by quantitative immunohistochemistry (IHC) using FL297. (2010) (2)
HIF inhibition in metastatic renal cell carcinoma (mRCC): Final results of a phase Ib /IIa clinical trial evaluating the nanoparticle drug conjugate (NDC), CRLX101, in combination with bevacizumab (bev). (2015) (2)
Tumor antigen expression and survival of patients with previously treated advanced non-small cell lung cancer (NSCLC) receiving viagenpumatucel-L (HS-110) plus nivolumab. (2020) (2)
Survival outcome segregated by KRAS mutation status in newly diagnosed stage IV non-small cell lung cancer (NSCLC) patients (pts) treated with first-line chemotherapy. (2012) (2)
Interim results of viagenpumatucel-L (HS-110) plus nivolumab in previously treated patients (pts) with advanced non-small cell lung cancer (NSCLC) in two treatment settings. (2021) (2)
Cisplatin (CIS) versus cetuximab (CET) with definitive concurrent radiotherapy (RT) for head and neck squamous cell carcinoma (HNSCC): An analysis of veteran’s health data. (2018) (2)
415 POSTER Dosing strategies for MLN8054, a selective Aurora A kinase inhibitor, based on pharmacokinetic modeling and simulations (2008) (2)
Outcomes Among Patients With Mucosal Head and Neck Squamous Cell Carcinoma Treated With Checkpoint Inhibitors. (2022) (2)
Phase I experience with an anti-glycotope monoclonal antibody, RAV12, in recurrent adenocarcinoma (2006) (2)
Abstract A254: A phase 1 safety and pharmacokinetic (PK) study of PI3K/TORC1/TORC2 inhibitor, XL765 (SAR245409), in combination with erlotinib in patients (pts) with advanced solid tumors (2009) (2)
A phase I trial of GEN-009, a neoantigen vaccine using ATLAS™, an autologous immune assay, to identify immunogenic and inhibitory tumour mutations (2019) (2)
A unique window of opportunity for practical reform of cancer clinical trials (2021) (2)
Phase II Trial of CDX-3379 and Cetuximab in Recurrent/Metastatic, HPV-Negative, Cetuximab-Resistant Head and Neck Cancer (2022) (2)
Treatment and Outcomes of Oropharyngeal Cancer in Patients with Human Immunodeficiency Virus. (2019) (2)
Survival and toxicity in patients with human papilloma virus‐associated oropharyngeal squamous cell cancer receiving trimodality therapy including transoral robotic surgery (2021) (2)
Pharmacokinetic (PK) and pharmacodynamic (PD) analysis from a phase I study of PF-03446962, a fully human mab against ALK1, a TGF-beta receptor involved in tumor angiogenesis. (2012) (2)
Proteins binding to regulatory elements 5' to the human beta-globin gene. (1989) (1)
Abstract LB-407: Down-modulation of mRNA by EZN-2968, an hypoxia-inducible factor-1α (HIF-1α) mRNA antagonist, administered in adult patients with advanced solid tumors (2011) (1)
P1.01-64 Impact of STK11 Co-Mutation on Outcomes Following Immunotherapy Among Patients with TP53 and KRAS Mutated Stage IV NSCLC (2018) (1)
Association of TP53 mutation status with clinical outcomes stratified by sensitive and non sensitive EGFR mutation, in non-small cell lung cancer (NSCLC). (2015) (1)
SAT0128 Prolonged Exposure to Subcutaneous and Intravenous Abatacept in Patients with Rheumatoid Arthritis does not Affect Rates of Infection, Malignancy and Autoimmune Events: Results from Pooled Clinical Trial Data (2013) (1)
The 2007 Inaugural ASTRO/ASCO/AHNS Multidisciplinary Head and Neck Cancer Symposium. (2007) (1)
OA07.01 Phase II Study of Pembrolizumab for Oligometastatic Non-Small Cell Lung Cancer (NSCLC) Following Completion of Locally Ablative Therapy (LAT) (2018) (1)
Pathological Factors Predicting the Risk of Distant Failure for Human Papillomavirus–Positive Oropharyngeal Squamous Cell Carcinoma (OPSCC) (2015) (1)
Phase II study of dalantercept, a novel inhibitor of ALK1-mediated angiogenesis, in patients with recurrent or metastatic squamous cell carcinoma of the head and neck. (2013) (1)
Phase I dose escalation study to assess tolerability and pharmacokinetics of recombinant human IL-18 (rhIL-18) administered as fourteen daily subcutaneous injections in patients with solid tumors. (2004) (1)
Platinum Re-Exposure as a Non-Small Cell Lung Cancer (NSCLC) Treatment Strategy in the Age of Immunotherapy. (2022) (1)
Pathological Factors Predicting the Risk of Distant Metastases for Human Papillomavirus–Positive Oropharyngeal Squamous Cell Carcinoma (OPSCC) (2016) (1)
P3.02c-069 Pretreatment Neutrophil-to-Lymphocyte Ratio (NLR) Predicts Outcomes with Nivolumab in Non-Small Cell Lung Cancer (NSCLC): Topic: IT Biomarkers (2017) (1)
HIF inhibition in mRCC: Planned interim analysis of CRLX101 with bevacizumab (bev), a phase 1b/2a. (2014) (1)
41 POSTER DCE-MRI endpoints reveal decreased tumor vascularity in patients with liver metastases: a Phase I dose escalating study with IMC-1121B (2008) (1)
Phase II Trial of Combination Nab-paclitaxel and Gemcitabine in Non-squamous Non-small Cell Lung Cancer After Progression on Platinum and Pemetrexed. (2022) (1)
Immune Checkpoint Inhibitor–Related Cardiovascular Toxicity in Lung Cancer (2019) (1)
MA06.01 Death From Intercurrent Disease After Proton- Versus Photon-Based Chemoradiotherapy for Non-Small Cell Lung Cancer (2021) (1)
1231 A phase I study of axitinib (AG-013736) combined with paclitaxel/carboplatin (P/C), gemcitabine/cisplatin (Gem/Cis) or pemetrexed/cisplatin (Pem/Cis) in patients (pts) with solid tumours, including advanced non-small cell lung cancer (NSCLC) (2009) (1)
Regulatory issues involved in hematopoietic growth factor approval. (1992) (1)
Phase I and pharmacokinetic trial of oral administration of CYC682, a novel 2' deoxycytidine type anti-metabolite pro-drug, in patients with advanced solid tumors or lymphoma (2005) (1)
PUB140 A Pilot Study to Assess Circulating Tumor Cells, Circulating Tumor Cell DNA and Cell Free DNA in Patients with Small Cell Lung Cancer (2017) (1)
P1.01-63 Impact of Prior Radiation Pneumonitis on Incidence of Immunotherapy Related Pneumonitis (2019) (1)
The ongoing roll-out of Aurora Kinase inhibitors in cancer treatment (2010) (1)
6508 ORAL CP-751, 871, an anti-IGF-IR antibody, in combination with paclitaxel and carboplatin or paclitaxel and carboplatin alone as first-line treatment for advanced non-small cell lung cancer (NSCLC): A phase Ib/randomized phase II, non-comparative, open label trial (2007) (1)
5507 ORAL A phase 2 study of axitinib (AG-013736; AG) in patients (pts) with advanced thyroid cancers (2007) (1)
P3-098: Multicenter, randomized phase II trial of CI–1033, an irreversible pan– erbB inhibitor, for previously treated advanced non–small cell lung cancer (2007) (1)
Abstract CT340: Phase 1b/2a study of the nanopharmaceutical CRLX101 with bevacizumab (bev) in the treatment of patients (pts) with refractory metastatic renal cell carcinoma (mRCC): results from the planned interim analysis (2014) (1)
A Single-institution Comparison of Cetuximab, Carboplatin, and Paclitaxel Induction Chemotherapy Followed by Chemoradiation (CRT) Versus CRT for Locally Advanced Squamous Cell Carcinoma of the Head and Neck (LA-SCCHN) (2016) (1)
Definitive Tumor Directed Therapy for Metachronous Oligometastatic HPV-Associated Oropharyngeal Cancer Following Trans-Oral Robotic Surgery. (2021) (1)
O-158 A randomized phase II ECOG trial of two dose levels of temsirolimus (CCI-779) in patients with extensive stage small cell lung cancer in remission after induction therapy (2005) (1)
Abstract A170: Results from the phase 1 portion of a phase 1/2 study of the irreversible PI-3K inhibitor PX-866 and docetaxel. (2011) (1)
A Phase II study of Viagenpumatucel-l (HS-110) in combination with low-dose Cyclophosphamide versus physician's choice in patients with advanced non-small cell lung cancer (2014) (1)
Abstract C122: Phase 1b relative bioavailability (BA) study of enteric coated tablet (ECT) in reference to powder in capsule (PIC) formulation of the investigational drug alisertib (MLN8237), an Aurora A Kinase (AAK) inhibitor, in patients with advanced nonhematologic malignancies. (2011) (1)
Outcomes in patients with metastatic non-small cell lung cancer (mNSCLC) with brain metastases treated with pembrolizumab-based therapy. (2020) (1)
Circulating tumor cells (CTCs) in patients (pts) with small cell lung cancer (SCLC) as a marker of disease burden and therapeutic response, and predictor of disease relapse. (2012) (1)
Axitinib (AG-013736; AG) in combination with paclitaxel (P)/carboplatin (C) in patients (pts) with advanced solid tumors (2007) (1)
First interim exploratory analysis of immune response in patients with advanced non-small cell lung cancer receiving viagenpumatucel-l (HS-110) in combination with low-dose cyclophosphamide in an ongoing phase II trial. (2015) (1)
81P Monalizumab in combination with cetuximab post platinum and anti-PD-(L)1 in patients with recurrent/metastatic squamous cell carcinoma of the head and neck (R/M SCCHN): Updated results from a phase II trial (2020) (1)
Long-term disease control of ≥2 years achieved with cabozantinib in subjects with metastatic medullary thyroid carcinoma on a phase I study. (2013) (1)
Lung Cancer–Related Mortality With Inhaled Insulin or a Comparator: Follow-up Study of Patients Enrolled in Exubera-Controlled Clinical Trials (FUSE) Final Results (2019) (1)
Physical Activity Barriers After Cancer Scale (2019) (1)
Case records of the Massachusetts General Hospital. Weekly clinicopathological exercises. Case 14-1966. Oat-cell carcinoma of lung, with extension to local lymph nodes, (associated with inappropriate secretion of antidiuretic hormone). (1966) (0)
Functional Outcomes in Patients with Human Papillomavirus-Associated Oropharyngeal Squamous Cell Cancer Treated with Trimodality Therapy. (2023) (0)
1028P Clinical results of a pilot trial of GEN-009, a neoantigen vaccine containing immunogenic tumour specific neoantigens, in combination with PD-1 inhibitors in advanced cancers (2020) (0)
Sequence-Binding Factors Identifies Two Distinct Proteins (0)
Abstract 4333: Association of TP53 mutation status with clinical outcomes in patients with EGFR mutated non-small cell lung cancer (NSCLC) (2015) (0)
EMERGING SAFETY AND ACTIVITY DATA FROM GEN- 009–101: A PHASE 1/2A TRIAL OF GEN-009, A NEOANTIGEN VACCINE IN COMBINATION WITH PD-1 CHECK-POINT INHIBITORS (CPI) IN ADVANCED SOLID TUMORS (2020) (0)
Viagenpumatucel-L (HS-110) plus nivolumab in patients with advanced non-small cell lung cancer (NSCLC). (2019) (0)
Stereotactic Body Radiation Therapy for Oligometastatic Pulmonary Lesions (2014) (0)
Cancer communication in the social media age: Could Twitter help clinical trial accrual? (2016) (0)
Abstract 2419: A phase Ib-IIa study evaluating the nanopharmaceutical CRLX101 in combination with bevacizumab in the treatment of patients (pts.) with advanced renal cell carcinoma. (2013) (0)
Fanconi anemia caused by biallelic inactivation of BRCA2 can present with an atypical cancer phenotype in adulthood (2022) (0)
Determination of the bioequivalence of a new oral topotecan formulation relative to the current formulation in patients with advanced solid tumors (2008) (0)
Vaccination of Patients with High-risk Melanoma in the Adjuvant Setting with a Purified gp 100 peptide: Trial Design and Preliminary Findings (1996) (0)
P2.07-059 Phase I Trial of Gene Mediated Cytotoxic Immunotherapy (GMCI) for Malignant Pleural Effusion (MPE) and Malignant Pleural Mesothelioma (MPM) (2017) (0)
P59.21 Impact of Reflex Testing on Pathology Based Molecular Testing in Patients With Advanced Non-Squamous Non-Small Cell Lung Cancer (NSCLC) (2021) (0)
Abstract CT236: INTERLINK-1: A phase 3, randomized, double-blind, placebo-controlled, multicenter, global study of monalizumab in combination with cetuximab in patients with recurrent or metastatic head and neck squamous cell carcinoma previously treated with an immune checkpoint inhibitor (2022) (0)
Tumor Infiltrating Lymphocytes in Occult Primary HPV+ Oropharyngeal Squamous Cell Carcinoma (OPSCC): Comparison of the Primary Tumor and Regional Lymph Node Metastases (2019) (0)
Analysis of the Relationship Between Response to Chemotherapy and Response to Radiation Therapy in Patients With Non-small Cell Lung Cancer Receiving Sequential Treatment (2012) (0)
Detection of Plasma Circulating Tumor-Tissue Modified HPV DNA Following Trans-Oral Robotic Surgery (TORS) and Neck Dissection for p16+ Oropharyngeal Squamous Cell Carcinoma. (2021) (0)
Comparative effectiveness of carboplatin-pemetrexed (Carbo-Pem) with vs. without bevacizumab (Bev) in patients with advanced non-squamous (Sq) non-small cell lung cancer (NSCLC). (2018) (0)
Uptake of first-line immune checkpoint inhibitors among medically frail patients with advanced solid malignancies. (2020) (0)
Sex-based differences in outcomes among surgically treated patients with HPV-related oropharyngeal squamous cell carcinoma. (2021) (0)
Investigational NEDD8-activating enzyme inhibitor pevonedistat (Pev) plus chemotherapy in patients (Pts) with solid tumors (Phase 1b study): Antitumor activity of pev plus carboplatin (Carbo)/paclitaxel (Pac). (2016) (0)
390 Emerging safety and activity data from GEN-009–101: A phase 1/2a trial of GEN-009, a neoantigen vaccine in combination with PD-1 check-point inhibitors (CPI) in advanced solid tumors (2020) (0)
Dynamic monitoring of circulating tumor DNA next-generation gene sequencing as a predictive biomarker of response and progression-free survival after pembrolizumab monotherapy in patients with advanced NSCLC. (2019) (0)
Utilization and Factors Precluding Receipt of Checkpoint Inhibitor Consolidation for Stage III NSCLC in a Large US Academic Health System. (2023) (0)
Translation factors and t cell activation (1990) (0)
Anesthesia Not Related to Fludarabine Toxicity (1993) (0)
Cancer Therapy: Clinical A Phase I Dose-Escalation Study of Danusertib (PHA-739358) Administered as a 24-Hour Infusion with and without Granulocyte Colony-Stimulating Factor in a 14-Day Cycle in Patients with Advanced Solid Tumors (2009) (0)
Treatment and Outcomes of Oropharyngeal Cancer in People with Human Immunodeﬁciency Virus (2019) (0)
Abstract CT237: Interim results of a first-in-human phase 1 study of the oral MET kinase inhibitor, LY2801653, in patients with advanced cancer (2014) (0)
Abstract B26: Phase 1b trial of investigational NEDD8-activating enzyme (NAE) inhibitor pevonedistat (TAK-924/MLN4924) in combination with docetaxel, paclitaxel/carboplatin, or gemcitabine in patients (pts) with solid tumors (2015) (0)
Abstract 783: Impact of KRAS and TP53 co-mutations on outcomes following 1st-line therapy among patients with LKB1/STK11 mutated stage IV NSCLC (2018) (0)
Treatment Package Time Impacts Locoregional Control for High Risk pl6+ Oropharyngeal Squamous Cell Carcinoma Treated with Transoral Robotic Surgery (TORS) and Postoperative Radiation (2019) (0)
Cost effectiveness of amifostine for prevention of radiation-induced xerostomia (2005) (0)
Pre-treatment 5-methyltetrahydrofolate levels and response to pemetrexed in stage IV adenocarcinoma of the lung. (2015) (0)
Management of Thyroid and Parathyroid Cancers (2011) (0)
Analysis of p16 expression by AQUA in non-small cell lung cancer (NSCLC) among non-smokers. (2011) (0)
Rheumatoid arthritis - treatment 180. Utility of Body Weight Classified Low-Dose Leflunomide in Japanese Rheumatoid Arthritis (2011) (0)
An open label phase I study of ABR-217620 in combination with docetaxel in patients with NSCLC. (2007) (0)
Comparative E ff ectiveness of Carboplatin / Pemetrexed With Versus Without Bevacizumab for Advanced NonsquamousNon – Small Cell LungCancer (2019) (0)
Clinical Studies Phase I Assessment of New Mechanism-Based Pharmacodynamic Biomarkers for MLN 8054 , a Small-Molecule Inhibitor of Aurora A Kinase (2011) (0)
Outcomes and prediction of lethal recurrence after transoral robotic surgery for HPV+ head and neck cancer. (2021) (0)
Improving comprehensive genotyping in patients with newly diagnosed non-squamous NSCLC: Results from a prospective trial of a behavioral nudge intervention. (2022) (0)
Abstract C16: Prospective real‐time analysis of p‐cadherin expression to select patients into a phase I oncology trial (2009) (0)
A Phase II Open-Label Trial of Binimetinib and Hydroxychloroquine in Patients With Advanced KRAS-Mutant Non-Small Cell Lung Cancer (2023) (0)
Early Tumor and Nodal Response in Patients with Locally Advanced Non-Small Cell Lung Carcinoma Predict for Oncologic Outcomes in Patients Treated with Concurrent Proton Therapy and Chemotherapy (2020) (0)
A Single Institution Experience With Induction Chemotherapy (ICT) Followed by Chemoradiation (CRT) Versus CRT for Definitive Treatment of Locally Advanced Squamous Cell Carcinoma of the Head and Neck (LA-SCCHN) (2012) (0)
485 Long term results from a phase 1 trial of GEN-009, a personalized neoantigen vaccine, combined with PD-1 inhibition in advanced solid tumors (2021) (0)
147 Phase I pharmacokinetic (PK) and safety study of the antiangiogenic peptide ATN-161 (Ac-PHSCN-NH2) in patients with solid tumors (2004) (0)
P2.04-02 Effect of Chemotherapy, Chemoimmunotherapy, and Immunotherapy on Parameters of T Cell Exhaustion in Metastatic Non-Small Cell Lung Cancer (2019) (0)
Bayesian approach to interpreting somatic cancer sequencing data: a case in point (2020) (0)
Real-world outcomes after second-line treatment in non-small cell lung cancer (NSCLC) patients treated with immunotherapy. (2020) (0)
P2.14-26 Outcomes in Patients with Compound Epidermal Growth Factor Receptor (EGFR) Mutations After Treatment with Tyrosine Kinase Inhibitors (TKIs) (2019) (0)
The Role of Advanced Imaging in Assessing Response to Definitive Chemoradiation Prior to Prophylactic Cranial Irradiation in Limited-Stage Small Cell Lung Cancer (2012) (0)
OA03.02 Outcomes of Patients with Metastatic Non-Small Cell Lung Cancer (MNSCLC) with Brain Metastases Treated with Pembrolizumab (2019) (0)
377 A phase 1, dose-escalation, safety, pharmacokinetic and pharmacodynamic study of PF-03732010, an IgG1 monoclonal antibody against P-cadherin (placental), administered to adult patients with advanced solid tumors (2010) (0)
Stereotactic Body Radiation Therapy for Oligometastatic Pulmonary Lesions: Metastatic Non-Small Cell Lung Cancer (2014) (0)
A phase I dose-escalation study of selumetinib in combination with docetaxel or dacarbazine in patients with advanced solid tumors (2017) (0)
Incorporation of plasma-based next-generation sequencing to improve guideline-concordant molecular testing in patients with newly diagnosed metastatic nonsquamous non-small cell lung cancer. (2021) (0)
Pharmacokinetic modeling and simulation (PK M&S) supported dose escalation of PF-03446962, a monoclonal antibody (mAb) against activin receptor like kinase 1, in patients with solid tumors. (2012) (0)
Phase II study of pemetrexed (P) and gemcitabine (G) in patients with advanced head and neck cancer (SCCHN). (2009) (0)
Death without progression as an endpoint to describe cardiac radiation effects in locally advanced non-small cell lung cancer (2023) (0)
Circulating immunecomplexes inprimary biliary cirrhosis: interactions withlymphoid cells (1982) (0)
Development of DNA affinity techniques for the functional characterization of purified RNA polymerase II transcription factors (1987) (0)
Uptake and effectiveness of checkpoint inhibitor therapy among trial-ineligible patients with advanced solid malignancies. (2021) (0)
1064PHigh-dose versus low-dose cisplatin with definitive concurrent radiotherapy for squamous cell carcinoma of the head and neck (SCC): An analysis of veteran’s health registry data (2017) (0)
How do we scale-up access to ARVs? Treatment now. (2003) (0)
Abstract B31: Viagenpumatucel-L (HS-110) plus nivolumab in previously treated patients with advanced non-small cell lung cancer (NSCLC) (2020) (0)
Multicenter P hase I I S tudy o f O ral B exarotene f or P atients With M etastatic B reast C ancer (2003) (0)
Patterns of Failure in Metastatic Epidermal Growth Factor Receptor-Mutated Non-Small Cell Lung Cancer: Implications for the Role of Definitive Local Therapy to the Primary Tumor. (2017) (0)
Problems With Interpreting Treatment Effects in Observational Competing Risks Data-Reply. (2022) (0)
Abstract CT126: A synthetic DNA plasmid encoding HPV6 E6 and E7 proteins in patients with HPV6-associated aerodigestive lesions (2020) (0)
Fluororescence in situ hybridization (FISH) gene amplification analysis of EGFR and HER2 in patients with malignant salivary gland tumors (MSGT) treated with lapatinib (2007) (0)
PD3-3-1: A phase Ib/randomized phase II, non-comparative, open label trial of paclitaxel and carboplatin with or without the anti-IGF-IR antibody CP-751,871 as first-line treatment for advanced non-small cell lung cancer (NSCLC) (2007) (0)
P1.15-07 Phase II Study of Pembrolizumab and Itacitinib for First Line Treatment of Metastatic NSCLC Expressing PD-L1 (2022) (0)
Weight Loss During Head and Neck Radiation: Risk Factors and Implications on Treatment Outcome (2012) (0)
Outcomes Using TORS or Definitive Chemoradiation for T3/T4 HPV+ Oropharynx Cancer. (2021) (0)
463 POSTER Phase I study of sapacitabine, an oral nucleoside analogue, in patients with refractory solid tumors or lymphomas (2006) (0)
Erratum to: A phase I dose-escalation study of Selumetinib in combination with Erlotinib or Temsirolimus in patients with advanced solid tumors (2017) (0)
Evaluation of a novel RNA biomarker of CDK2 inhibition in phase 1 clinical trials with BMS-387032. (2004) (0)

This paper list is powered by the following services:

What Schools Are Affiliated With Roger B. Cohen?

Roger B. Cohen is affiliated with the following schools:

McGill University
Emory University
Indiana University
University of Texas Health Science Center at San Antonio
Shanghai Jiao Tong University
University of Bern
Duke University
University of Pennsylvania